[ET Net News Agency, 23 January 2025] UBS raised the target price for Wuxi Bio (02269)
to HKD20.3 from HKD11.5 and maintained the "neutral" rating.
The research house said with Wuxi XDC becoming a strong revenue driver for Wuxi Bio, it
notes the portfolio is more skewed to early stage projects, which could benefit Wuxi Bio's
R&D stage revenue growth. (rc)